Stock Events

Stock Events

Cytodyn 

€0.24
0
+€0.01+2.61% Friday 12:46

Statistics

Day High
0.26
Day Low
0.24
52W High
0.36
52W Low
0.17
Volume
5,055
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

8AprExpected
Next
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 296.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences is a biopharmaceutical company that competes with CytoDyn in the HIV and other antiviral drug markets, making it a direct competitor.
GSK
GSK
Mkt Cap113.29B
GlaxoSmithKline, through its HIV drugs division ViiV Healthcare, competes in the HIV treatment space, directly challenging CytoDyn's efforts.
Merck
MRK
Mkt Cap298.84B
Merck & Co., Inc. offers a range of antiviral and immunotherapy products that compete with CytoDyn's treatments for various diseases, including HIV.
Johnson & Johnson
JNJ
Mkt Cap585.7B
Johnson & Johnson, through its pharmaceutical division Janssen, develops treatments for HIV/AIDS, making it a competitor in the same market as CytoDyn.
Pfizer
PFE
Mkt Cap161.09B
Pfizer is involved in the development of drugs for infectious diseases, including HIV, which puts it in competition with CytoDyn.
Arbutus Biopharma
ABUS
Mkt Cap875.74M
Arbutus Biopharma Corporation works on antiviral therapies, including for HIV, potentially competing with CytoDyn's product pipeline.
Vertex Pharmaceuticals
VRTX
Mkt Cap111.43B
Vertex Pharmaceuticals is engaged in the creation of treatments for a range of diseases, including viral infections, which could make it a competitor to CytoDyn.
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Bristol Myers Squibb has a portfolio of HIV treatments that compete with CytoDyn's offerings in the HIV therapy market.
Incyte
INCY
Mkt Cap19.09B
Incyte Corporation works on drugs for various diseases, including those with antiviral applications, potentially putting it in competition with CytoDyn.

About

CytoDyn Inc. operates as a clinical-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor in the areas of human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), oncology, and such as coronavirus disease (COVID-19). It is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
Show more...
CEO
Dr. Jacob P. Lalezari M.D.
Employees
9
Country
United States
ISIN
US23283M1018

Listings

STU
DE
296.STU
MU
DE
296.MU
OTC Link
US
CYDY

0 Comments

Share your thoughts

FAQ

What is Cytodyn stock price today?▼
The current price of 296.STU is €0.24 EUR — it has increased by +2.61% in the past 24 hours. Watch Cytodyn stock price performance more closely on the chart.
What is Cytodyn stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Cytodyn stocks are traded under the ticker 296.STU.
Is Cytodyn stock price growing?▼
296.STU stock has risen by +2.61% compared to the previous week, the month change is a -0% fall, over the last year Cytodyn has showed a +38.82% increase.
When is the next Cytodyn earnings date?▼
Cytodyn is going to release the next earnings report on July 29, 2026.
How many employees does Cytodyn have?▼
As of April 12, 2026, the company has 9 employees.
In which sector is Cytodyn located?▼
Cytodyn operates in the Health & Wellness sector.
When did Cytodyn complete a stock split?▼
Cytodyn has not had any recent stock splits.
Where is Cytodyn headquartered?▼
Cytodyn is headquartered in Vancouver, United States.